Risk factors for the failure of antimuscarinic treatment with solifenacin in women with overactive bladder.

[1]  S. Hsiao,et al.  Factors associated with a better therapeutic effect of solifenacin in patients with overactive bladder syndrome , 2014, Neurourology and urodynamics.

[2]  T. Kessler,et al.  Efficacy and adverse events of antimuscarinics for treating overactive bladder: network meta-analyses. , 2012, European urology.

[3]  K. Burgio,et al.  Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA/SUFU guideline. , 2012, The Journal of urology.

[4]  C. Spino,et al.  Anticholinergic therapy vs. onabotulinumtoxina for urgency urinary incontinence. , 2012, The New England journal of medicine.

[5]  S. Kraus,et al.  Efficacy and tolerability of fesoterodine in older and younger subjects with overactive bladder. , 2010, Urology.

[6]  V. Nitti,et al.  Can we predict which patient will fail drug treatment for overactive bladder? A think tank discussion , 2010, Neurourology and urodynamics.

[7]  C. Chapple,et al.  Listening to the patient: a flexible approach to the use of antimuscarinic agents in overactive bladder syndrome , 2009, BJU international.

[8]  D. Staskin,et al.  Re: Giacomo Novara, Antonio Galfano, Silvia Secco, et al. A systematic review and meta-analysis of randomized controlled trials with antimuscarinic drugs for overactive bladder. Eur Urol 2008;54:740-64. , 2009, European urology.

[9]  R. Freeman,et al.  An International Urogynecological Association (IUGA)/International Continence Society (ICS) joint report on the terminology for female pelvic floor dysfunction , 2010, International Urogynecology Journal.

[10]  L. Cardozo,et al.  Solifenacin in the treatment of urgency and other symptoms of overactive bladder: results from a randomized, double‐blind, placebo‐controlled, rising‐dose trial , 2008, BJU international.

[11]  L. Cardozo,et al.  Urinary incontinence at orgasm: relation to detrusor overactivity and treatment efficacy. , 2008, European urology.

[12]  V. Ficarra,et al.  A systematic review and meta-analysis of randomized controlled trials with antimuscarinic drugs for overactive bladder. , 2008, European urology.

[13]  Z. Gabriel,et al.  The effects of antimuscarinic treatments in overactive bladder: an update of a systematic review and meta-analysis. , 2008, European urology.

[14]  F. Ghezzi,et al.  Efficacy of tolterodine in women with detrusor overactivity and anterior vaginal wall prolapse: is it the same? , 2007, BJOG : an international journal of obstetrics and gynaecology.

[15]  K. Coyne,et al.  Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. , 2006, European urology.

[16]  S. Colman,et al.  A validated patient reported measure of urinary urgency severity in overactive bladder for use in clinical trials. , 2005, The Journal of urology.

[17]  L. Matza,et al.  Test‐retest reliability of four questionnaires for patients with overactive bladder: The overactive bladder questionnaire (OAB‐q), patient perception of bladder condition (PPBC), urgency questionnaire (UQ), and the primary OAB symptom questionnaire (POSQ) , 2005, Neurourology and urodynamics.

[18]  J. Ouslander,et al.  Management of Overactive Bladder , 2004, CNS Spectrums.

[19]  R. Bump,et al.  Validation of two global impression questionnaires for incontinence. , 2003, American journal of obstetrics and gynecology.

[20]  P. Abrams,et al.  How widespread are the symptoms of an overactive bladder and how are they managed? A population‐based prevalence study , 2001, BJU international.

[21]  L. Brubaker,et al.  The standardization of terminology of female pelvic organ prolapse and pelvic floor dysfunction. , 1996, American journal of obstetrics and gynecology.